News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MGI Pharma Inc. (MOGN) And SuperGen, Inc. (SUPG) Release: Dacogen(TM) (Decitabine) Injection Complete Response Accepted For Review By U.S. FDA


12/16/2005 12:15:38 PM

MINNEAPOLIS & DUBLIN, Calif.--(BUSINESS WIRE)--Dec. 15, 2005--MGI PHARMA, INC. (Nasdaq:MOGN) and SuperGen, Inc. (Nasdaq:SUPG) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Companies' resubmission as of November 15, 2005 as a complete response to the Approvable Letter for Dacogen(TM) (decitabine) injection for myelodysplastic syndromes (MDS). The resubmission has been classified by the FDA as a Class 2 response, and the FDA has established a user fee goal to review this response by May 15, 2006.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES